Fusion Antibodies (LON:FAB) Stock Price Down 8.1% – What’s Next?

Fusion Antibodies plc (LON:FAB) shares dropped 8.1% during mid-day trading on Tuesday . The stock traded as low as GBX 12.20 and last traded at GBX 12.56. Approximately 1,593,241 shares changed hands during mid-day trading, an increase of 238% from the average daily volume of 470,916 shares. The stock had previously closed at GBX 13.67.

Fusion Antibodies Stock Performance

The stock has a market capitalization of £15.75 million, a PE ratio of -8.40 and a beta of 1.22. The firm’s fifty day moving average is GBX 13.14 and its 200-day moving average is GBX 13.79. The company has a current ratio of 1.80, a quick ratio of 2.36 and a debt-to-equity ratio of 92.42.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.